Liquidia’s Chief Commercial Officer, Scott Moomaw, has exercised and immediately sold 80,000 shares of common stock, as reported in a recent SEC filing. This transaction, valued at approximately $2.83 million based on a weighted average sale price of $35.32, is notably larger than Moomaw’s recent median sell of around 4,849 shares since January 2025, indicating a significant liquidity management move rather than a shift in his investment strategy.
The timing of the sale aligns with Liquidia’s strong market performance, as the company has seen a remarkable 159.4% total return over the past year, driven by the successful launch of its inhaled treprostinil product, Yutrepia, which generated $90.1 million in Q4 2025. Moomaw’s remaining equity position of 188,954 shares, alongside 25,300 stock options, suggests continued alignment with shareholder interests despite the recent sale.
Investors should view this transaction as a routine liquidity exercise rather than a sign of distress, especially as Liquidia moves towards profitability and works on developing a longer-lasting version of its pulmonary hypertension therapy.
Source: fool.com